Hospira Shares Up 20.9% Since SmarTrend's Buy Recommendation (HSP)
Comtex SmarTrend(R) - Tue Dec 23, 5:05PM CST
SmarTrend identified an Uptrend for Hospira (NYSE:HSP) on October 24th, 2014 at $51.84. In approximately 2 months, Hospira has returned 20.89% as of today's recent price of $62.67.
HSP: 62.60 (-0.07)
Hospira to Present at the J.P. Morgan 33rd Annual Healthcare Conference Jan. 14, 2015
PR Newswire - Fri Dec 19, 3:30PM CST
Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that the company will present at the J.P. Morgan 33rd Annual Healthcare Conference on Wednesday, Jan. 14, 2015, in San Francisco.
JPM: 62.48 (unch), HSP: 62.60 (-0.07)
Is Boston Scientific (BSX) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 3:50PM CST
On Dec 16, 2014, Zacks Investment Research upgraded Boston Scientific Corporation (BSX) to a Zacks Rank #2 (Buy).
MGNX: 33.00 (+0.34), BSX: 13.13 (+0.07), ABAX: 58.48 (+0.22), HSP: 62.60 (-0.07)
Uptrend Call Working As Hospira Stock Rises 15.8% (HSP)
Comtex SmarTrend(R) - Tue Dec 16, 11:11AM CST
SmarTrend identified an Uptrend for Hospira (NYSE:HSP) on October 24th, 2014 at $51.84. In approximately 2 months, Hospira has returned 15.76% as of today's recent price of $60.01.
HSP: 62.60 (-0.07)
Family of executed Ohio inmate sues expert witness
By ANDREW WELSH-HUGGINS - AP - Tue Dec 16, 9:36AM CST
COLUMBUS, Ohio (AP) — The state's former expert witness on lethal injection should have known that a condemned inmate would suffer because of a two-drug combo that had never been used before, the inmate's family said in a lawsuit.
MCK: 209.79 (+0.58), HSP: 62.60 (-0.07)
2015 Healthcare Sector Predictions
Leonard Yaffe - Seeking Alpha - Tue Dec 16, 5:50AM CST
Below, I shall review my 2013 and 2014 predictions, as well as share my thoughts on the year ahead. Below are my 2014 Predictions: 1. An increase (however modest) of those without prior health insurance, combined with an improving economy, will...
HYH: 42.62 (-0.24), ABT: 45.70 (-0.02), BIIB: 340.89 (+5.13), MCK: 209.79 (+0.58), CAH: 82.07 (+0.15), DPLO: 29.90 (+0.49), PFE: 31.42 (-0.03), KMB: 117.77 (-0.21), HSP: 62.60 (-0.07), CELG: 109.60 (+3.48), JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), CVS: 97.89 (+0.02), AGIO: 109.67 (+2.45), REGN: 400.12 (+6.07)
Hospira Rises 4.53% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Dec 11, 4:45PM CST
Hospira (NYSE:HSP) traded in a range yesterday that spanned from a low of $59.44 to a high of $63.08. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $61.30 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HSP: 62.60 (-0.07)
Hospira Set to Possibly Pullback After Yesterday's Rally of 4.53%
Comtex SmarTrend(R) - Thu Dec 11, 4:44PM CST
Hospira (NYSE:HSP) traded in a range yesterday that spanned from a low of $59.44 to a high of $63.08. Yesterday, the shares gained 4.5%, which took the trading range above the 3-day high of $61.30 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HSP: 62.60 (-0.07)
Update: Cubist Pharmaceuticals Is Acquired By Merck, Gains Remain For Investors
David Zanoni - at Seeking Alpha - Wed Dec 10, 11:31PM CST
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), HSP: 62.60 (-0.07)
Merck-Cubist Deal On Despite Patent Setback, Shares Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 3:30PM CST
Merck (MRK) intends to go ahead with the Cubist acquisition despite the recent unfavorable court ruling regarding Cubicin.
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), TEVA: 57.09 (+0.33), HSP: 62.60 (-0.07)
Merck-Cubist deal going ahead
at Investor's Business Daily - Tue Dec 09, 5:42PM CST
The $9.5 bil acquisition is advancing, even though Cubist Pharma's (CBST) lead drug may face generic competition sooner than expected. The companies announced the deal Mon., hours before a federal judge in Del. ruled as invalid 4 of 5 Cubist patents...
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), HSP: 62.60 (-0.07)
Cubist Shoots Up on $9.5 Billion Buyout Offer from Merck - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 3:30PM CST
Merck (MRK) is set to acquire Cubist in an all-cash transaction valued at about $9.5 billion or $102 per share which will strengthen its hospital acute care portfolio.
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), BIOD: 1.36 (-0.04), HSP: 62.60 (-0.07)
Merck-Cubist Deal Is On Despite Patent Setback
at Investor's Business Daily - Tue Dec 09, 10:27AM CST
Big pharma Merck affirmed Tuesday that it's going ahead with its $9.5 billion acquisition of biotech Cubist Pharmaceuticals even though Cubist's lead drug looks to face generic competition sooner than expected. Merck (MRK) stock was down 4.5% in...
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), MYL: 56.97 (+0.39), FMS: 37.40 (+0.15), TEVA: 57.09 (+0.33), HSP: 62.60 (-0.07)
Merck committed to Cubist after patent losses
By TOM MURPHY - AP - Tue Dec 09, 9:27AM CST
Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a federal court invalidated most of the patents protecting the company's top-selling antibiotic just hours after that deal was announced Monday.
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), TEVA: 57.09 (+0.33), HSP: 62.60 (-0.07)
Wall Street Breakfast: China Stocks Tumble Most Since 2009
Wall Street Breakfast - Seeking Alpha - Tue Dec 09, 5:31AM CST
Economy European stocks fell for a second day as German imports and exports contracted in October, while Tesco ( OTCPK:TSCDF , OTCPK:TSCDY ) and energy companies plunged. German October imports slid 3.1% from a month earlier, while exports...
AMZN: 303.03 (-3.26), DRC: 81.19 (-0.10), VRX: 140.33 (-0.22), TLM: 7.84 (unch), C: 54.54 (+0.12), DB: 30.95 (+0.04), FIVE: 38.76 (-0.11), HSP: 62.60 (-0.07), ARO: 2.30 (-0.03), AGN: 210.12 (+0.95), PBR: 7.60 (-0.11), SPY: 207.77 (+0.02), QQQ: 104.30 (+0.09), CBST: 100.29 (-0.09), SMFG: 7.29 (+0.03), BHP: 46.95 (-0.36), MRK: 57.46 (+0.25), HMC: 30.37 (+0.14)
16.0% Return Seen to Date on SmarTrend Hospira Call (HSP)
Comtex SmarTrend(R) - Mon Dec 08, 5:58PM CST
SmarTrend identified an Uptrend for Hospira (NYSE:HSP) on October 24th, 2014 at $51.84. In approximately 2 month, Hospira has returned 15.97% as of today's recent price of $60.12.
HSP: 62.60 (-0.07)
Merck, Cubist slip AH; Hospira gets favorable ruling
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 5:11PM CST
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), HSP: 62.60 (-0.07)
You Can Outsmart Wall Street With These 3 Stocks
Motley Fool Staff - Motley Fool - Sat Dec 06, 11:32AM CST
Source: Flickr user snowlepard. Many investors look to Wall Street for guidance when it comes to which stocks they should be buying and selling. But truth be told, Wall Street analysts are just as fallible as you and I. Many great companies often...
LUK: 22.44 (-0.27), BOH: 58.90 (-0.03), HSP: 62.60 (-0.07)
Meet 5 Top Drug Stocks That Are Bolting Past Market
at Investor's Business Daily - Tue Dec 02, 7:02AM CST
Celgene and Amgen are among the highly rated companies on IBD's Screen Of The Day, Bolting RS Lines. The Relative Strength line measures how a stock performs compared to the S&P 500 index. RS lines hitting new highs before the actual stock is a...
SHPG: 209.29 (+0.07), AZN: 70.44 (+0.26), AMGN: 160.67 (+3.15), AMAG: 43.02 (+0.90), ABBV: 66.21 (+1.86), HSP: 62.60 (-0.07), CELG: 109.60 (+3.48)